The efficacy of VUMERITY is based upon bioavailability studies comparing dimethyl fumarate (DMF) to VUMERITY in patients with relapsing forms of MS and healthy subjects1
VUMERITY offers the established efficacy of DMF across Studies 1 and 2
In Study 1 and Study 2 pivotal trials, DMF demonstrated a 53% and 44% relative reduction in annualized relapse rate (ARR) vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)1
Most common adverse reactions (incidence for DMF ≥10% and ≥2% more than placebo) were, respectively, flushing (40% and 6%), abdominal pain (18% and 10%), diarrhea (14% and 11%), and nausea (12% and 9%)
MORE PATIENTS HAVE STARTED VUMERITY THAN ANY OTHER BRANDED ORAL THERAPY FOR RMS IN THE US SINCE DECEMBER 20202,a
aBased on the cumulative number of new MS prescriptions for the months December 2020 through February 2023 per IQVIA NPA New to Brand, Patient Insights® monthly NBRx.